- Home
- OSK vs GH Comparison
OSK vs GH Comparison
Compare OSK & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSK
- GH
- Stock Information
- Founded
- OSK 1917
- GH 2011
- Country
- OSK United States
- GH United States
- Employees
- OSK N/A
- GH N/A
- Industry
- OSK Auto Manufacturing
- GH Medical Specialities
- Sector
- OSK Consumer Discretionary
- GH Health Care
- Exchange
- OSK Nasdaq
- GH Nasdaq
- Market Cap
- OSK 5.6B
- GH 4.9B
- IPO Year
- OSK N/A
- GH 2018
- Fundamental
- Price
- OSK $109.07
- GH $49.14
- Analyst Decision
- OSK Buy
- GH Strong Buy
- Analyst Count
- OSK 14
- GH 20
- Target Price
- OSK $120.29
- GH $54.35
- AVG Volume (30 Days)
- OSK 799.5K
- GH 2.2M
- Earning Date
- OSK 08-01-2025
- GH 08-06-2025
- Dividend Yield
- OSK 1.88%
- GH N/A
- EPS Growth
- OSK N/A
- GH N/A
- EPS
- OSK 9.37
- GH N/A
- Revenue
- OSK $10,499,200,000.00
- GH $773,996,000.00
- Revenue This Year
- OSK N/A
- GH $23.14
- Revenue Next Year
- OSK $5.73
- GH $21.42
- P/E Ratio
- OSK $11.61
- GH N/A
- Revenue Growth
- OSK 5.69
- GH 28.20
- 52 Week Low
- OSK $76.82
- GH $20.14
- 52 Week High
- OSK $118.39
- GH $52.92
- Technical
- Relative Strength Index (RSI)
- OSK 63.36
- GH 62.17
- Support Level
- OSK $109.25
- GH $48.00
- Resistance Level
- OSK $111.19
- GH $51.71
- Average True Range (ATR)
- OSK 2.45
- GH 2.67
- MACD
- OSK -0.18
- GH 0.39
- Stochastic Oscillator
- OSK 75.77
- GH 78.60
About OSK Oshkosh Corporation (Holding Company)Common Stock
Oshkosh Corp is the top producer of access equipment, specialty vehicles, and military trucks. It serves diverse end markets, where it is typically the market share leader in North America, or, in the case of JLG aerial work platforms. The company had manufactured joint light tactical vehicles for the U.S. Department of Defense. The company reports in three segments: Access, Vocational and Defense. It derives maximum revenue from Access Segment.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.